Last reviewed · How we verify

NCT04923204

Utility of the Pharmacogenetic Information Provided by NEUROPHARMAGEN in the Treatment of Bipolar Depressionwith Bipolar Depression

Completed Last updated 11 June 2021
What this trial tests

trial testing Pharmacogenomic-testing with NEUROPHARMAGEN in Bipolar Disorder in 76 participants. Completed in 5 December 2019.

Timeline
1 March 2016
Primary endpoint
31 March 2016
5 December 2019

Quick facts

Lead sponsorAB Biotics, SA
StatusCompleted
Study typeOBSERVATIONAL
Enrollment76
Start date1 March 2016
Primary completion31 March 2016
Estimated completion5 December 2019
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

AB Biotics, SA — full company profile →

Who can join

18 and older, any sex, with Bipolar Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of the impact of the genetic variation of individual genes on the therapeutic response and side effects profile in a cohort of well-characterized patients with bipolar depression, using NEUROPHARMAGEN.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Genetic Variations Associated with Long-Term Treatment Response in Bipolar Depression.
    Anmella G, Vilches S, Espadaler-Mazo J, Murru A, et al · · 2021 · cited 3× · PMID 34440433 · DOI 10.3390/genes12081259

Verify or expand the search:

Other recruiting trials for Bipolar Disorder

Currently open trials in the same condition.

Other AB Biotics, SA trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04923204.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing